What is Myriad Genetics's cancer care continuum — revenue?

Myriad Genetics (MYGN) reported cancer care continuum — revenue of $120.2M in Q1 2026.

What does cancer care continuum — revenue mean?

This metric represents the total revenue generated from diagnostic testing services and companion diagnostics focused on hereditary cancer risk assessment and oncology treatment guidance. It captures the financial performance of products designed to identify genetic predispositions and support clinical decision-making throughout the patient's cancer care journey. This segment is a primary indicator of the company's market penetration and adoption rates within the molecular oncology diagnostics sector.

Myriad Genetics MYGN Cancer Care Continuum — Revenue

Other product segments

Hereditary Cancer

$96.8M+2.5%

Prenatal

$44.9M0.0%

Prenatal Health

$41.9M—

Mental Health

$38.3M—

Similar metrics at other companies

MIRCancer care — Total revenues

$55.3M+8.4%

BLLNOncology — Revenue

$10.72M+392%

GHOncology — Total Revenue

$204.95M+36.1%

NTRAOncology — Revenue recognized

$100K0.0%

LLYOncology — Revenue

$2.27B+16.4%

LNTHOncology — Revenue

$240.92M-6.5%

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's cancer care continuum — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's cancer care continuum — revenue?: Myriad Genetics (MYGN) reported cancer care continuum — revenue of $120.2M in Q1 2026.
What does cancer care continuum — revenue mean?: This metric represents the total revenue generated from diagnostic testing services and companion diagnostics focused on hereditary cancer risk assessment and oncology treatment guidance. It captures the financial performance of products designed to identify genetic predispositions and support clinical decision-making throughout the patient's cancer care journey. This segment is a primary indicator of the company's market penetration and adoption rates within the molecular oncology diagnostics sector.